Drug Profile
CALAA 01
Alternative Names: CALAA-01Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Calando Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Ribonucleotide reductase inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 31 Aug 2012 Calando completes enrolment in its phase Ib trial for refractory Solid tumours in the US
- 09 Aug 2011 Calando completes enrolment in its phase I trial for Solid tumours in the US